Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.12.2 (
MEK
)
18,161
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Interleukin-2
(
IL-2
) is the major growth factor of activated T lymphocytes. By inducing cell cycle progression and protection from apoptosis in these cells,
IL-2
is involved in the successful execution of an immune response. Upon binding its receptor,
IL-2
activates a variety of signal transduction pathways, including the Ras/
mitogen-activated protein kinase kinase
(
MEK
)/extracellular signal-regulated kinase (ERK) and Janus kinase (JAK)/STAT cascades. In addition, activation of phosphatidylinositol 3-kinase (PI3K) and several of its downstream targets has also been shown. However, the coupling of STAT3 serine phosphorylation to PI3K in response to
IL-2
has yet to be shown in either T cell lines or primary human T cells. This report shows that the PI3K inhibitors LY294002 and wortmannin block activation of
MEK
and ERK by
IL-2
in primary human T cells. Moreover, these inhibitors significantly reduce
IL-2
-triggered STAT3 serine phosphorylation without affecting STAT5 serine phosphorylation. Analysis of the effects of these inhibitors on cell cycle progression and apoptosis strongly suggests that PI3K-mediated events, which includes STAT3 activation, are involved in
IL-2
-mediated cell proliferation but not cell survival. Finally, results presented illustrate that in primary human T cells, activation of Akt is insufficient for
IL-2
-induced anti-apoptosis. Thus, these results demonstrate that
IL-2
stimulates PI3K-dependent events that correlate with cell cycle progression, but not anti-apoptosis, in activated primary human T cells.
...
PMID:IL-2 activation of a PI3K-dependent STAT3 serine phosphorylation pathway in primary human T cells. 1268 50
Major histocompatibility complex class I-related chain (MICA) is a cell stress-regulated molecule recognized by cytotoxic cells expressing the NKG2D molecule. MICA can be induced on T cells after CD3 or CD28 engagement. Here, we investigated the intracellular pathways leading to activation-induced expression of MICA. The Src kinase inhibitor PP1 inhibited up-regulated expression of MICA on anti-CD3-stimulated T cells. Downstream signaling routes involved mitogen-activated protein kinase (MAPK) kinase (
MEK
)1/extracellular signal-regulated kinase (ERK), p38 MAPK, and calcineurin, as MICA expression was prevented by U0126, SB202190, cyclosporin A, and FK506. Also, Lck and Fyn as well as
MEK1
/ERK and p38 MAPK were found to regulate MICA expression in anti-CD28/phorbol 12-myristate 13-acetate-stimulated T cells. Expression of MICA on activated T cells involved
interleukin-2
-dependent signaling routes triggered by Janus tyrosine kinases/signal transducer and activators of transcription and p70(S)(6) kinase, as it could be inhibited by AG490 and rapamycin. This is the first demonstration of the intracellular pathways involved in activation-induced expression of MICA, which may reveal potential targets for immune intervention to modulate MICA expression in pathological disorders.
...
PMID:Up-regulated expression of MICA on activated T lymphocytes involves Lck and Fyn kinases and signaling through MEK1/ERK, p38 MAP kinase, and calcineurin. 1277 14
Keratinocytes are an important component of the skin immune system, and keratinocyte-derived cytokines control the function of Langerhans cells. We previously showed that CX-659S, a novel diaminouracil derivative, had an inhibitory effect on hapten-induced contact hypersensitivity reaction in mice. In this study, we investigated the mechanism by which CX-659S elicits its inhibitory effect. CX-659S inhibited the expressions of CD80 and CD86, but not that of CD54, on Langerhans cells in epidermal cell suspensions. Exogenous granulocyte-macrophage colony-stimulating factor restored the CX-659S-induced inhibition of CD80 and CD86 expressions of Langerhans cells. The production of
interleukin-2
from allogeneic T cells was also inhibited when the cells were stimulated with CX-659S-treated epidermal cells, and this inhibition was suppressed by the addition of granulocyte-macrophage colony-stimulating factor during CX-659S treatment. As CX-659S significantly inhibited production of granulocyte-macrophage colony-stimulating factor from keratinocytes, CX-659S was thought to indirectly affect Langerhans cells by inhibiting the function of keratinocytes. These effects of CX-659S were preceded by blockade of the phosphorylation of extracellular-signal-regulated kinase 1/2 and their direct activators, mitogen-activated protein kinase/extracellular-signal-regulated kinase 1/2 (
MEK1
/2), but not p38 mitogen-activated protein kinase or inhibitory nuclear factor kappaBalpha, in keratinocytes. Furthermore, a specific
MEK1
/2 inhibitor, U0126, mimicked the effect of CX-659S. CX-659S, a keratinocyte-response modifier, would be an effective therapeutic compound to inhibit contact hypersensitivity reaction, its action mechanism being different from those of other immunosuppressive agents such as glucocorticosteroids or cyclosporine A.
...
PMID:CX-659S, a diaminouracil derivative, indirectly inhibits the function of Langerhans cells by blocking the MEK1/2-Erk1/2 pathway in keratinocytes. 1278 25
The mechanism of action of immune suppression by cannabinoids involves suppression of
interleukin-2
(
IL-2
) production in phorbol ester plus calcium ionophore (PMA/Io)-stimulated lymphocytes. This decrease in
IL-2
was due to inhibition of activator protein-1 (AP-1) and nuclear factor of activated T cells (NF-AT) transcription factors, both of which depend on proteins that are regulated by the extracellular signal-regulated kinase subgroup of the mitogen-activated protein kinases (ERK MAPK). Thus, the objective of the present study was to characterize the effects of cannabinoid compounds on ERK MAPK under conditions where
IL-2
expression was suppressed. Using the
MEK
inhibitor PD098059 in order to assess the role of ERK MAPK in PMA/Io-stimulated splenocytes (SPLC), it was determined that
IL-2
production and expression of c-fos and c-jun nuclear protein expression depended on activation of ERK MAPK. In response to PMA/Io, expression of nuclear phosphorylated ERK MAPK was rapidly induced, peaked at approximately 15 min, and was sustained for up to 240 min. Pretreatment with cannabinol (CBN) inhibited expression of phosphorylated ERK MAPK at several time points up to 240 min post cellular activation. Furthermore, WIN-55212-2, a synthetic cannabinoid, inhibited expression of phosphorylated ERK MAPK at 240 min post cellular activation. CBN did not induce activation of ERK MAPK in the absence of PMA/Io. Collectively, these studies suggest that cannabinoid-induced inhibition of
IL-2
in PMA/Io-stimulated splenocytes might be due, in part, to inhibition of ERK MAPK activation.
...
PMID:Cannabinoids inhibit the activation of ERK MAPK in PMA/Io-stimulated mouse splenocytes. 1294 47
Gab2 (Grb2-associated binder-2), a member of the IRS (insulin receptor substrate)/Gab family of adapter proteins, undergoes tyrosine phosphorylation in response to cytokine or growth factor stimulation and serves as a docking platform for many signal transduction effectors, including the tyrosine phosphatase SHP-2 [SH2 (Src homology 2)-domain-containing tyrosine phosphatase]. Here, we report that, following IL-2 (
interleukin-2
) stimulation of human T lymphocytes, SHP-2 binds tyrosine residues 614 and 643 of human Gab2 through its N- and C-terminal SH2 domains respectively. However, the sole mutation of Tyr-614 into phenylalanine is sufficient to prevent Gab2 from recruiting SHP-2. Expression of the Gab2 Tyr-614-->Phe (Y614F) mutant, defective in SHP-2 association, prevents ERK (extracellular-signal-regulated kinase) activation and expression of a luciferase reporter plasmid driven by the c-fos SRE (serum response element), indicating that interaction of SHP-2 with Gab2 is required for ERK activation in response to IL-2. Further investigation of IL-2-dependent induction of SRE showed that expression of a constitutively active mutant of the RhoA GTPase synergizes with IL-2 for SRE-driven transcription, whereas a dominant-negative mutant reduces the IL-2 response. Thus, in response to IL-2, full induction of the SRE requires ERK-dependent as well as Rho-dependent signals that target the Ets-box and the CArG-box respectively. We also report that the synergy between Gab2/SHP-2 and RhoA for IL-2-dependent CArG-box-driven transcription depends upon
MEK
(mitogen-activated protein kinase/ERK kinase) activation, and is likely to involve regulation of the serum response factor co-activator MAL. Our studies thus provide new insights into the role of Gab2 and SHP-2 in IL-2 signal transduction.
...
PMID:Interaction of the tyrosine phosphatase SHP-2 with Gab2 regulates Rho-dependent activation of the c-fos serum response element by interleukin-2. 1517 Mar 89
A T cell receptor (TCR) recognizes and responds to an antigenic peptide in the context of major histocompatibility complex-encoded molecules. This provokes T cells to produce
interleukin-2
(
IL-2
) through extracellular signal-regulated kinase (ERK) activation. We investigated the roles of B-Raf in TCR-mediated
IL-2
production coupled with ERK activation in the Jurkat human T cell line. We found that TCR cross-linking could induce up-regulation of both B-Raf and Raf-1 activities, but Raf-1 activity was decreased rapidly. On the other hand, TCR-stimulated kinase activity of B-Raf was sustained. Expression of a dominant-negative mutant of B-Raf abrogated sustained but not transient TCR-mediated
MEK
/ERK activation. The inhibition of sustained ERK activation by either expression of a dominant-negative B-Raf or treatment with a
MEK
inhibitor resulted in a decrease of the TCR-stimulated nuclear factor of activated T cells (NFAT) activity and
IL-2
production. Collectively, our data provide the first direct evidence that B-Raf is a positive regulator of TCR-mediated sustained ERK activation, which is required for NFAT activation and the full production of
IL-2
.
...
PMID:B-Raf contributes to sustained extracellular signal-regulated kinase activation associated with interleukin-2 production stimulated through the T cell receptor. 1533 34
CD4+CD25+ regulatory T cells (Tregs) are essential negative regulators of immune responses. Here, we examined the signaling properties of human Tregs, using CD4+CD25+ Treg and CD4+CD25- control (Tcont) cell lines generated from cord blood. Treg cell lines were markedly hyporesponsive to stimulation with dendritic cells and with anti-CD3/CD28-coated beads. Hyporesponsiveness was reversed by exogenous
interleukin-2
(
IL-2
). T-cell receptor (TCR)-CD3/CD28-mediated activation of Rap1 and Akt was retained in Tregs, but activation of Ras, mitogenactivated protein kinase 1/2 (
MEK1
/2), and extracellular signal-regulated kinase 1/2 (Erk1/2) was impaired. Tregs were blocked from cell cycle progression due to decrease of cyclin E and cyclin A and increase of p27kip1 (p27kip cyclin dependent kinase inhibitor).
IL-2
induced sustained increase of cyclin E and cyclin A and prevented up-regulation of p27kip1. Tregs had high susceptibility to apoptosis that was reversed by
IL-2
, which correlated with activation of Erk1/2, up-regulation of Bcl-x(L) (B-cell CLL/lymphoma 2-like nuclear gene encoding mitochondrial protein, transcript variant 2), and phosphorylation of Bad (Bcl2 antagonist of cell death) at Ser112. Thus, Tregs share biochemical characteristics of anergy, including abortive activation of Ras-
MEK
-Erk, increased activation of Rap1, and increased expression of p27kip1. In addition, our results indicate that TCR-CD3/CD28-mediated and IL-2 receptor-mediated signals converge at the level of
MEK
-Erk kinases to regulate Treg survival and expansion and suggest that manipulation of the
MEK
-Erk axis may represent a novel strategy for Treg expansion for immunotherapy.
...
PMID:CD4+CD25+ regulatory T-cell lines from human cord blood have functional and molecular properties of T-cell anergy. 1602 May 8
Activation of T lymphocytes through costimulation of the T cell receptor/CD3 complex (TCR/CD3) and coreceptors (e.g. CD2 or CD28) leads to production of the growth factor
interleukin-2
(
IL-2
) and subsequent proliferation. For these activation processes, remodelling of the actin cytoskeleton plays an important functional role. We have shown that the activity of the actin-remodelling protein cofilin is crucially involved in T lymphocyte activation processes. In unstimulated human peripheral blood T lymphocytes (PB-T) cofilin exists in its inactive ser-3-phosphorylated form. T lymphocyte activation through costimulation of TCR plus the coreceptors CD28 or CD2, respectively, induces the dephosphorylation of cofilin. Concomitantly, cofilin associates with the actin cytoskeleton. The functional importance of cofilin for T lymphocyte activation was shown employing cell permeable peptides which block binding of cofilin to actin. In human PB-T these peptides impair the formation of the immunological synapse and inhibit the induction of T lymphocyte proliferation and cytokine production. The serine phosphatases PP1 and PP2A dephosphorylate cofilin in T lymphocytes. Importantly, a PKC-Ras-
MEK
/PI3K-cascade links costimulation of PB-T through TCR/CD3 and CD28 to activation of cofilin through dephosphorylation. Notably, the induction of cofilin dephosphorylation requires the combined activities of two Ras-effectors, namely
MEK
and PI3K. With respect to PI3K, this result was unexpected since so far it was generally assumed that-unlike in other cell types-Ras is not able to activate PI3K in T lymphocytes, as concluded from experiments performed with the human T-lymphoma line Jurkat. This discrepancy implied that the signalling events upstream of PI3K differ between PB-T and Jurkat cells. In line with this, we found that in PB-T the PI3K-inhibitors wortmannin and LY294002 block activation induced cofilin dephosphorylation and its association with the actin cytoskeleton. In Jurkat cells, however, where cofilin is present mainly in its non-phosphorylated form and permanently associated with the actin cytoskeleton, wortmannin and LY294002 do not block these events. Studies by others employing these PI3K-inhibitors have also led to such contradictory results: While in stimulated PB-T these inhibitors repress expression of
IL-2
, they even enhance
IL-2
expression in Jurkat cells. These findings show that signalling events in Jurkat cells are not representative for signalling processes in untransformed human T lymphocytes. Importantly, our data demonstrate that-rebutting a persistent dogma-a T-cell specific uncoupling of PI3K from Ras does not exist.
...
PMID:Ras initiates phosphatidyl-inositol-3-kinase (PI3K)/PKB mediated signalling pathways in untransformed human peripheral blood T lymphocytes. 1608 47
The major T cell growth factor
interleukin-2
(
IL-2
) is secreted by activated T cells in response to antigenic stimulation. This requires signal transduction via the CD3/TCR complex and the CD28 coreceptor, leading to activation of mitogen-activated protein kinase (MAPK) and calcineurin/NF-AT signaling pathways. We observed that simian immunodeficiency virus derived from African green monkeys (SIVagm3) is a potent activator of
IL-2
gene expression.
IL-2
promoter studies in A3.01 T cells demonstrated that SIVagm3 induced an up to 38-fold increased transcriptional activation of the
IL-2
promoter. Inhibition of MAPK signaling pathways using inhibitors of
MEK
, JNK or p38 abolished SIVagm3-induced
IL-2
activation in a dose-dependent manner. In contrast, the immunosuppressive drug cyclosporin A (CyA), a classical
IL-2
inhibitor that blocks calcineurin activity, had no effect. Consistent with this finding, the nuclear factor of activated T cells (NF-AT), which is activated by calcineurin, was not induced by SIVagm3. Analyzing further transcription factor binding sites located on the
IL-2
promoter we found that SIVagm3 did mainly promote transcriptional activation of the CD28/AP-1 and NF-kappaB responsive elements. These DNA elements were also induced by the viral transactivator protein (Tat) and expression of Tat was sufficient to activate
IL-2
induction in stimulated cells. Our results show that SIVagm3 is capable of stimulating
IL-2
gene expression via molecular mechanisms different from those induced during classical T cell activation.
...
PMID:IL-2 induction by simian immunodeficiency virus involves MAP kinase signaling but is independent of calcineurin/NF-AT activity. 1612 42
Common lymphoid progenitors (CLPs) are lymphoid-lineage-committed progenitor cells. However, they maintain a latent myeloid differentiation potential that can be initiated by stimulation with
interleukin-2
(
IL-2
) via ectopically expressed
IL-2
receptors. Although CLPs express IL-7 receptors, which share the common gamma chain with
IL-2
receptors, IL-7 cannot initiate lineage conversion in CLPs. In this study, we demonstrate that the critical signals for initiating lineage conversion in CLPs are delivered via IL-2 receptor beta (IL-2R beta) intracellular domains. Fusion of the A region of the IL-2R beta cytoplasmic tail to IL-7R alpha enables IL-7 to initiate myeloid differentiation in CLPs. We found that Shc, which associates with the A region, mediates lineage conversion signals through the mitogen activated protein kinase (MAPK) pathway. Because
mitogen-activated protein kinase kinase
(
MEK
)/extracellular signal-regulated kinase (ERK) inhibitors completely blocked
IL-2
-mediated lineage conversion, MAPK activation, specifically via the
MEK
/ERK pathway, is critically involved in the initiation of this event. Furthermore, formation of granulocyte/macrophage (GM) colonies by hematopoietic stem cells, but not by common myeloid progenitors (CMPs), was severely reduced in the presence of
MEK
/ERK inhibitors. These results demonstrate that activation of
MEK
/ERK plays an important role in GM lineage commitment.
...
PMID:Activation of mitogen-activated protein kinase kinase (MEK)/extracellular signal regulated kinase (ERK) signaling pathway is involved in myeloid lineage commitment. 1753 16
<< Previous
1
2
3
4
5
Next >>